Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Not yet recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

not_yet_recruiting375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_1

A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)

NCT07854483
not_yet_recruitingphase_1

A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis

NCT07825389
not_yet_recruitingphase_2

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

NCT07729826
withdrawnphase_1

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

NCT06935474

Clinical Trials (4)

Showing 4 of 4 trials
NCT07854483Phase 1

A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)

Not Yet Recruiting
NCT07825389Phase 1

A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis

Not Yet Recruiting
NCT07729826Phase 2

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

Not Yet Recruiting
NCT06935474Phase 1

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4